Veracyte Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Veracyte (VCYT)

Veracyte shares fell more than 50% after its Nov. 4, 2026 third-quarter report said Decipher Prostate test volume was below expectations. The company lowered its projected annual test volume from about 20,000 (±1,000) to 12,000–15,000, and 2026 revenue guidance to $590–$593 million, described as a $3 million reduction from the prior range’s upper end; testing revenue guidance fell from $576–$582 million to roughly $572 million. Levi & Korsinsky announced an investigation into whether statements about Decipher Prostate’s growth outlook were accurate and complete.

Analysis

The key issue is whether Decipher weakness is a temporary forecasting miss or evidence that adoption is structurally below the curve embedded in Veracyte’s prior outlook. The headline volume change and the comparatively modest consolidated revenue reset do not map cleanly: first verify whether the cited 20,000 figure referred to incremental tests rather than total Decipher volume, and reconcile the test-volume and revenue guidance bridges. Otherwise, investors risk extrapolating an apples-to-oranges comparison. If the weakness persists, the larger risk is not just near-term revenue but a lower confidence premium on Veracyte’s growth pipeline; that can keep the multiple under pressure even if non-Decipher products cushion reported revenue. Potential substitution beneficiaries include Myriad Genetics, MDxHealth and Exact Sciences, but the article provides no evidence of share gains, so this is not yet a peer-pair signal.

The more than 50% decline likely discounts substantial disappointment; chasing a short immediately has poor asymmetry, while a dip-buy assumes a recovery not yet evidenced. Over the next 1–3 months, the decisive catalysts are management’s explanation of ordering/utilization, any revised product-level volume outlook, and the next reported Decipher volumes. Over 6–18 months, sustained weakness would challenge the growth case; stabilization would support the view that this was a forecast reset rather than an adoption break. The law-firm investigation is solicitation, not a finding of misconduct or a near-term fundamental catalyst.

Key Decisions for Investors

• Avoid an immediate directional trade after the gap; treat VCYT as an event-risk watch until the company clarifies whether the cited volume outlook is incremental or total and provides a reconciled revenue bridge.
• Do not buy the dip solely on the size of the selloff. Reassess after the next Decipher volume disclosure; a further cut or continued deterioration in ordering would support a bearish thesis, while stabilization with guidance intact would falsify it.
• If subsequent data confirm persistent weakness, consider a defined-risk bearish position only after post-event option volatility normalizes; cap exposure because the initial repricing may already reflect a large portion of the reset.
• Monitor Myriad Genetics, MDxHealth and Exact Sciences for evidence of competitive share capture, but do not establish a peer pair without comparable product-level volume or utilization data.